Major results of a phase III comparative multicenter study on the follitropin alfa biosimilar (Primapur®) and the original follitropin alfa (Gonal-f®)

Major results of a phase III comparative multicenter study on the follitropin alfa biosimilar (Primapur®) and the original follitropin alfa (Gonal-f®)

A clinical study on the efficacy and safety of follitropin alfa has been conducted. The aim of the study was to confirm the therapeutic equivalence between the follitropin alfa biosimilar (Primapur®) and the reference medication (Gonal-f®) in controlled induction of superovulation within the assiste...

Full description

Bibliographic Details
Main Authors: Z. B. Barakhoeva, L. A. Vovk, I. V. Zorina, N. Yu. Belousova, T. A. Teterina, S. A. Yakovenko, V. P. Apryshko, Yu. A. Fetisova, N. A. Marilova, E. G. Morozova, M. M. Ovchinnikova, M. A. Tishenko, Yu. V. Sherbatyuk, A. V. Kolotovkina, A. A. Miskun, G. V. Kasyanova, L. G. Sichinava, R. I. Shalinа, M. A. Polzikov
Format: Article
Language:Russian
Published: IRBIS LLC 2018-11-01
Series:Акушерство, гинекология и репродукция
Subjects:
follitropin alfa
recombinant follicle-stimulating hormone
biosimilar
in vitro fertilization
assisted reproductive technologies
Online Access:https://www.gynecology.su/jour/article/view/506

Internet

https://www.gynecology.su/jour/article/view/506

Similar Items